Challenging and Defending BioPharma Patents at the PTAB – What Practitioners Need to KnowAugust 13, 2014
IPR and CBM petitions present unique opportunities and issues in the biopharma area for both branded and generic companies. The number of petitions being filed in this area is growing steadily. Listen in as we explored strategic issues related to post-grant practice, Hatch-Waxman litigation, and biosimilars.
Gwilym Attwell, Principal, Delaware